4024-05-9

Basic information

• Product Name: (R)-2-hydroxypropaniMidaMide hydrochloride
• Synonyms: (R)-2-hydroxypropaniMidaMide hydrochloride;(2R)-2-hydroxypropaniMidaMide hydrochloride;(2R)-2-HydroxypropaniMidaMide Monohydrochloride;(2R)-2-hydroxypropaniMidaMide HCl;(R )-(+)-2-Hydroxypropionamidine hydrochlorid;(2R)-2-Hydroxypropanamidine hydrochloride
• CAS NO: 4024-05-9
• Molecular Formula: C₃H₈N₂O*ClH
• Molecular Weight: 124.56936
• EINECS: -0
• Mol File: 4024-05-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (R)-2-hydroxypropaniMidaMide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-hydroxypropaniMidaMide hydrochloride(4024-05-9)
• EPA Substance Registry System: (R)-2-hydroxypropaniMidaMide hydrochloride(4024-05-9)

Safety Data

• Hazardous Substances Data: 4024-05-9(Hazardous Substances Data)

Usage

General Description

(R)-2-hydroxypropaniMidaMide hydrochloride, also known as (R)-1-(2-hydroxypropyl)pyrrolidine-2-carboxamide hydrochloride, is a chemical compound used in pharmaceutical research. It is a hydrochloride salt form of the R-enantiomer of 2-hydroxypropaniMidaMide, which is a derivative of the amino acid proline. (R)-2-hydroxypropaniMidaMide hydrochloride is known for its potential as a chiral building block in the synthesis of pharmaceuticals and other biologically active molecules. It is also used as a catalyst in organic synthesis and in the preparation of chiral ligands for asymmetric catalysis. Its unique molecular structure and chirality make it a valuable tool in the development of new drugs and chemical processes.

Upstream product

• 598-81-2 (R)-lactamide 

Downstream Products

• 912587-25-8 (2R)-N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzoimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropanimidamide 

Relevant articles and documents

Sorbitol dehydrogenase inhibitors

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.